![Can Cbd Gummies Make You Test Positive For A Drug Test? [KZEJU5Z7uSj]](https://i0.wp.com/cedclinic.com/wp-content/uploads/2026/08/ced-pexels-28153356.jpg?resize=150%2C150&ssl=1 "Can Cbd Gummies Make You Test Positive For A Drug Test? 1")
| Audience | Medical cannabis patients using CBD:THC combination products, cannabis clinicians and prescribers counseling on ratios and titration, primary care physicians fielding questions about CBD ‘balancing’ THC, and researchers studying cannabinoid drug interactions |
| Primary Topic | A systematic review and meta-analysis of 14 acute human dosing trials (341 participants) examining whether co-administered CBD changes the plasma pharmacokinetics of THC and its active metabolite 11-hydroxy-THC, published in Neuroscience and Biobehavioral Reviews in 2026 |
| Source | Read the study in Neuroscience and Biobehavioral Reviews (open access) | More access here |
Does CBD Change How Your Body Handles THC? A New Meta-Analysis Says Yes
A PROSPERO-registered systematic review pooled 14 acute dosing trials and 341 participants to test whether CBD changes the body’s handling of THC. Co-administered CBD was linked to significantly higher total THC exposure and to higher peak and total exposure of THC’s active metabolite, 11-hydroxy-THC, with evidence certainty ranging from very low to medium. The effect was concentrated at CBD doses of 100 mg or more and was larger with oral CBD than with inhaled CBD.
| Study Type | PRISMA-guided systematic review and meta-analysis of acute dosing trials, PROSPERO-registered (CRD42023480695) |
| Included Studies | 14 studies: 12 crossover, 2 parallel-group designs |
| Administration Routes | 7 oral (ingestion or oral spray/drops), 5 inhalation, 1 intravenous, 1 mixed IV and oral |
| Participants | 341 total across all included studies |
| Search Window | Systematic search through 24 November 2025 |
| Comparator | A single, fixed dose of THC alone versus a matched dose of THC co-administered with CBD |
| Primary Endpoints | Cmax, AUCt, and AUCinf of circulating THC and its active metabolite, 11-hydroxy-THC (11-OH-THC) |
| Statistical Approach | Random-effects meta-analyses pooling Hedges’ g and ratio of means (RoM); meta-regression testing CBD and THC dose-effects |
| Risk of Bias Tool | Cochrane Collaboration RoB 2 |
| THC Cmax Finding | Not significantly affected by CBD co-administration (Hedges’ g = 0.118, 95% CI -0.127 to 0.362), very low certainty evidence |
| THC AUCt Finding | Significantly higher with CBD co-administration versus THC alone (Hedges’ g = 0.526, 95% CI 0.222 to 0.830), very low certainty evidence |
| 11-OH-THC Cmax Finding | Significantly higher with CBD co-administration (Hedges’ g = 0.428, 95% CI 0.115 to 0.741), medium certainty evidence |
| 11-OH-THC AUCt Finding | Significantly higher with CBD co-administration (Hedges’ g = 0.692, 95% CI 0.284 to 1.099), medium certainty evidence |
| Dose Threshold Effect | For 11-OH-THC, studies using CBD doses of 100 mg or more found much larger increases (Cmax g = 1.584; AUCt g = 1.889) than studies using CBD doses under 100 mg (Cmax g = 0.085; AUCt g = 0.203), a significant between-group difference (P less than 0.001 for both) |
| Route Comparison | Oral CBD produced larger increases in 11-OH-THC (Cmax g = 0.774; AUCt g = 1.050) than inhaled CBD (Cmax g = 0.026, not significant; AUCt g = 0.147) |
| Meta-Regression Finding | CBD dose showed a significant dose-effect on Hedges’ g for 11-OH-THC Cmax and AUCt (P less than 0.05), but not for THC levels |
| Authors’ Conclusion | Cannabis users and prescribers of cannabinoid-based products should be aware of the potential for pharmacokinetic drug-drug interactions between CBD and THC, particularly with high doses of CBD |
| Journal | Neuroscience and Biobehavioral Reviews, volume 190, article 106910 (open access) |
| Published | Published online 20 August 2026; November 2026 print issue |
| DOI | 10.1016/j.neubiorev.2026.106910 | More access here |
| PMID | 42623982 |
| Affiliations | Centre Hospitalier de l’Université de Montréal (CHUM) Research Centre; Department of Psychiatry and Addiction, Université de Montréal |
Following PRISMA guidelines and a PROSPERO-registered protocol (CRD42023480695), the authors systematically searched for acute dosing trials that administered a single, fixed dose of THC to one study arm and a matched dose of THC co-administered with CBD to another, then compared circulating THC and 11-hydroxy-THC pharmacokinetics between arms.
Fourteen studies met inclusion criteria: 12 used crossover designs and two used parallel-group designs, covering oral administration (seven studies, combining ingestion with oral spray or drops), inhalation (five studies), intravenous administration (one study), and a mixed intravenous-and-oral protocol (one study), for a combined 341 participants.
Rather than relying on subjective reports of intoxication, the review focused on hard pharmacokinetic endpoints: Cmax (peak concentration), AUCt (exposure over the measured time course), and AUCinf (total exposure) for both THC and its active metabolite, 11-hydroxy-THC.
Random-effects meta-analyses pooled Hedges’ g standardized mean differences and ratio-of-means estimates across the 14 studies, and every included study’s risk of bias was graded using the Cochrane Collaboration’s RoB 2 tool.
Average AUCt of THC was significantly higher in study arms where CBD was co-administered compared with THC-only arms (Hedges’ g = 0.526, 95% CI 0.222 to 0.830). The authors rated this finding as very low certainty evidence, meaning it should be interpreted cautiously despite reaching statistical significance.
By contrast, THC’s peak concentration (Cmax) was not significantly affected by CBD co-administration (Hedges’ g = 0.118, 95% CI -0.127 to 0.362). This is an important distinction: co-administered CBD appears to extend or increase overall THC exposure over time rather than raise the highest blood level reached.
Both the peak concentration (Cmax) and total exposure (AUCt) of 11-hydroxy-THC, the active metabolite that itself contributes to THC’s psychoactive and physiological effects, were significantly higher with CBD co-administration: Cmax showed a Hedges’ g of 0.428 (95% CI 0.115 to 0.741) and AUCt showed a Hedges’ g of 0.692 (95% CI 0.284 to 1.099). Both findings were rated medium certainty evidence, notably stronger evidence grading than the THC findings themselves.
Meta-regression analysis found that CBD dose had a significant effect on the size of the 11-hydroxy-THC Cmax and AUCt findings (P less than 0.05), meaning higher CBD doses were associated with a larger metabolite effect. This same dose-response relationship was not observed for THC levels directly.
Subgroup analysis found this was strongly dose-dependent. For 11-hydroxy-THC, studies using CBD doses of 100 mg or more found much larger increases (Cmax Hedges’ g = 1.584; AUCt Hedges’ g = 1.889) than studies using CBD doses under 100 mg (Cmax g = 0.085; AUCt g = 0.203), a statistically significant between-group difference (P less than 0.001 for both).
Route of administration mattered too: oral CBD produced substantially larger increases in 11-hydroxy-THC (Cmax g = 0.774; AUCt g = 1.050) than inhaled CBD (Cmax g = 0.026, not significant; AUCt g = 0.147). Three of the oral studies using the highest CBD doses in the review (105 mg, 450 mg, and 640 mg) each linked the resulting rise in 11-hydroxy-THC to increased subjective, psychomotor, or cognitive effects.
THC is converted to 11-hydroxy-THC mainly by the liver enzymes CYP2C9 and CYP2C19. The review’s authors note that CBD is a known inhibitor of both enzymes, and cite one of their included trials, which found that 640 mg of oral CBD taken with 20 mg THC also significantly raised blood levels of losartan and omeprazole, two drugs used specifically to test CYP2C9 and CYP2C19 activity, alongside the rise in THC and 11-hydroxy-THC.
The authors are careful to note this is a proposed explanation supported by that one probe-drug study, not something this meta-analysis set out to test directly across all 14 trials.
The review’s authors state plainly that cannabis users and prescribers of cannabinoid-based products should be made aware of the potential for pharmacokinetic drug-drug interactions between CBD and THC, particularly with high doses of CBD, rather than assuming CBD is pharmacokinetically inert alongside THC.
CBD:THC ratio products have become a mainstay of medical and adult-use cannabis markets, frequently marketed and recommended on the premise that CBD offsets or smooths THC’s psychoactive effects, an idea that circulates in clinical and consumer conversations, and even in some public health guidance recommending high CBD:THC ratio products, without a strong pooled pharmacokinetic evidence base behind it.
This review adds a rigorously pooled, quantitative answer to that long-running question, and its central finding, that CBD co-administration is associated with higher THC and especially higher 11-hydroxy-THC exposure, particularly at higher CBD doses and with oral administration, runs counter to the common assumption that CBD simply tempers THC’s effects. It is, by the authors’ own account, the first meta-analysis on this specific question, following an earlier systematic review of the same literature that found equivocal results without pooling the data quantitatively.
In more than 20 years of practicing evidence-based cannabis medicine, I have heard the assumption that ‘CBD balances out the THC’ stated as though it were settled pharmacology, when in reality the human pharmacokinetic evidence behind that claim has been thin and scattered. This review is valuable precisely because it pools the acute dosing trials that actually measured blood levels rather than relying on how a study’s authors, or patients, described the subjective experience.
The finding I find most clinically actionable is not the overall, pooled result, it is the dose threshold. The metabolite effect was modest below 100 mg of CBD and became large, with a statistically significant jump, at 100 mg and above, and it was more pronounced with oral CBD than inhaled. That metabolite, 11-hydroxy-THC, is not a pharmacological afterthought; it is active and may be as potent as THC itself. For patients titrating higher-dose oral CBD:THC products in particular, this is exactly the kind of finding that belongs in the conversation about expectations for onset, duration, and the assumption that added CBD automatically means a gentler experience. I would not change practice based on one review of acute, single-dose studies, but it strengthens the case for individualized titration, extra caution at higher oral CBD doses, and not assuming a fixed CBD:THC ratio behaves predictably across patients or products.
How to Read a Pharmacokinetic Meta-Analysis Without Overreaching
A finding that CBD ‘significantly increases’ THC and metabolite exposure can sound like a clear clinical directive at first glance.
Five checks keep this review’s real, more limited contribution in view.
A Five-Step Reading Frame
Check the certainty rating, not just the p-value
The THC AUCt finding was statistically significant but rated very low certainty by the authors; only the 11-hydroxy-THC findings reached medium certainty.
Separate blood levels from lived experience
This review measured plasma pharmacokinetics, not subjective intoxication, driving impairment, or other clinical outcomes.
Notice which parameter moved
THC’s total exposure (AUCt) rose, but its peak concentration (Cmax) did not change significantly, a distinction easy to lose in a one-line summary.
Mind the dose and the route
The metabolite effect was small below 100 mg of CBD and grew sharply at 100 mg and above, and was larger with oral CBD than inhaled CBD.
Note that every trial was acute and single-dose
None of the 14 included studies tested chronic or repeated co-administration, the pattern most patients actually follow.
The Same Study Can Mean Different Things Depending on the Question Being Asked
Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses.
CBD May Not Simply ‘Soften’ Your THC Product
If you use a CBD:THC combination product on the assumption that CBD makes THC gentler or more predictable, this review found the opposite pharmacokinetic pattern: CBD co-administration was linked to higher THC exposure and higher exposure to THC’s active metabolite, especially at CBD doses of 100 mg or more and with oral products.
This does not mean every CBD:THC product will feel stronger, but it is a reason to titrate carefully and track your own response rather than assuming CBD automatically reduces THC’s impact, particularly with higher-dose oral products.
A Pharmacokinetic Basis for Individualized Titration
For clinicians recommending CBD:THC combination products, this review offers pooled pharmacokinetic evidence, rather than anecdote, that CBD co-administration can meaningfully raise exposure to THC’s active metabolite in a dose-responsive way, with the clearest effect above 100 mg of CBD and with oral dosing.
That supports counseling patients toward slow, individualized titration and closer monitoring specifically when moving into higher-dose oral CBD:THC regimens, rather than assuming a fixed ratio will behave the same way across products or people.
One Headline Finding Was Very Low Certainty
The most quoted result, that CBD raises THC’s AUCt, was rated very low certainty evidence by the review’s own authors, with most contributing studies individually rated high risk of bias, a caveat that is easy to lose in a simple summary of statistical significance.
Only the 11-hydroxy-THC findings reached medium certainty, and even the strongest subgroup result, the high-dose CBD effect, rests on just four studies.
A Useful Answer to a Common Patient Question
Primary care physicians frequently field questions from patients about whether adding CBD changes how THC affects them, often without a clear evidence base to draw on beyond product marketing claims.
This review supports a more precise, honest answer: current pooled evidence suggests CBD may increase rather than decrease THC and metabolite exposure, especially at higher CBD doses taken orally, though the clinical significance of that change is not yet established.
Acute Dosing Only, Considerable Heterogeneity
Every included trial used a single, acute dose rather than the chronic or repeated co-administration pattern that reflects real-world CBD:THC product use, limiting how far these findings can be extrapolated to typical patient behavior.
Heterogeneity between studies was high across every outcome (I-squared roughly 85 to 97 percent), and the great majority of individual studies were rated high risk of bias, even though the pooled subgroup and dose-response findings held up in sensitivity analyses.
A Reason to Revisit Ratio-Based Marketing Claims, Especially at High CBD Doses
Cannabis product formulations built around the premise that CBD predictably tempers THC’s effects may need to account for pharmacokinetic evidence suggesting the opposite direction of effect, particularly for the active 11-hydroxy-THC metabolite in higher-CBD oral products.
This does not invalidate CBD:THC ratio products, but it argues for more cautious, evidence-grounded language around what a given ratio and dose is expected to do pharmacokinetically, especially above roughly 100 mg of CBD.
Relevant to Impairment and Safety Conversations, With Caveats
Public health messaging about cannabis impairment, including driving safety, sometimes recommends high CBD:THC ratio products as lower-risk; this review’s pharmacokinetic findings complicate that assumption at higher CBD doses without yet proving a change in real-world impairment.
Communicating this nuance accurately, a plausible, dose-dependent pharmacokinetic signal that has not yet been linked to functional impairment, matters for avoiding both false reassurance and premature alarm.
A Case for Chronic-Dosing and Functional Outcome Studies
Because every included trial used acute, single-dose protocols, this review highlights a clear gap: no controlled evidence yet describes how CBD co-administration affects THC and metabolite exposure under real-world, repeated dosing, particularly at the higher CBD doses now common in consumer products.
Future trials that pair chronic co-administration pharmacokinetics with functional and subjective outcome measures, and that directly test the CYP2C9/CYP2C19 mechanism proposed here, would directly address the questions patients and clinicians are actually asking.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan
Want to discuss this topic with other patients and caregivers? Join the forum discussion
Frequently Asked Questions
What did this new study look at?
A PRISMA-guided, PROSPERO-registered systematic review and meta-analysis pooled 14 acute human dosing trials, comprising 341 participants, that compared a fixed dose of THC alone against a matched dose of THC co-administered with CBD, examining the resulting plasma pharmacokinetics of THC and its active metabolite, 11-hydroxy-THC.
What routes of administration were included?
The 14 included studies used oral administration (seven studies, combining ingestion with oral spray or drops), inhalation (five studies), intravenous administration (one study), and a mixed intravenous-and-oral protocol (one study), for a combined 341 participants across 12 crossover and two parallel-group designs.
Did CBD increase THC levels in the blood?
It increased THC’s total exposure (AUCt) but not its peak level. Average AUCt of THC was significantly higher in study arms where CBD was co-administered compared with THC-only arms, with a Hedges’ g of 0.526 (95% CI 0.222 to 0.830, very low certainty evidence). THC’s peak concentration (Cmax), by contrast, was not significantly affected (Hedges’ g = 0.118).
What happened to THC’s active metabolite, 11-hydroxy-THC?
Both the peak concentration (Cmax) and total exposure (AUCt) of 11-hydroxy-THC were significantly higher with CBD co-administration, with Hedges’ g values of 0.428 and 0.692 respectively. Both findings were rated medium certainty evidence, stronger than the THC findings themselves.
Did higher doses of CBD produce a bigger effect?
Yes, substantially so for the metabolite. Studies using CBD doses of 100 mg or more found much larger increases in 11-hydroxy-THC (Cmax Hedges’ g = 1.584; AUCt g = 1.889) than studies using CBD doses under 100 mg (Cmax g = 0.085; AUCt g = 0.203), and meta-regression confirmed CBD dose significantly predicted the size of the metabolite effect (P less than 0.05). This dose-response relationship was not observed for THC levels directly.
Did the route of CBD administration matter?
Yes. Oral CBD produced larger increases in 11-hydroxy-THC (Cmax g = 0.774; AUCt g = 1.050) than inhaled CBD (Cmax g = 0.026, not significant; AUCt g = 0.147), suggesting oral CBD:THC products may carry a stronger version of this interaction than inhaled products.
Does this mean CBD makes THC products stronger?
It means CBD co-administration was linked to higher measured plasma exposure to THC and its active metabolite in these controlled trials, especially with higher-dose oral CBD. Whether that translates into a stronger subjective or functional effect for a given patient was not directly tested by this review, which measured blood levels rather than intoxication or impairment outcomes.
Do the researchers know why this happens?
They propose a likely mechanism rather than proving one directly: CBD is a known inhibitor of CYP2C9 and CYP2C19, the liver enzymes that convert THC into 11-hydroxy-THC. One included trial found that CBD co-administration also raised blood levels of two drugs used to test those same enzymes, offering direct, though limited, supporting evidence.
Does this apply to people who use CBD and THC together regularly?
Not directly. All 14 included trials used acute, single-dose protocols. None tested chronic or repeated co-administration, which is how most patients actually use CBD:THC combination products over time.
What should patients using CBD:THC ratio products take from this?
This review is a reason to titrate CBD:THC combination products carefully, especially oral products with 100 mg or more of CBD, and track individual response rather than assuming a given ratio will predictably soften or reduce THC’s effects. It is not a reason to avoid these products, but it does support individualized dosing conversations with a clinician.
What do the study authors recommend?
The authors conclude that cannabis users and prescribers of cannabinoid-based products should be made aware of the potential for pharmacokinetic drug-drug interactions between CBD and THC, particularly with high doses of CBD, rather than assuming the two cannabinoids are pharmacokinetically independent.
